Loading stock data…
Crescent Biopharma, Inc. (CBIO)
N/A
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States.
Historical Price
No chart data available for CBIO
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.04M↓ | $10.84M | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$24.73M↑ | -$91.49M↓ | -$25.89M↓ | -$21.03M↓ | -$14.22M |
| Net Income | -$23.28M↑ | -$92.40M↓ | -$24.61M↓ | -$21.79M↓ | -$15.15M |
Peer Comparison
JNJUNHPFE
Fundamentals
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to trea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$495.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-88.16%
Volume
Today's trading volume
-
Recent News
Crescent Biopharma: Q4 Earnings Snapshot
WALTHAM, Mass. AP) — Crescent Biopharma, Inc. CBIO) on Thursday reported a loss of $92.4 million in its fourth quarter.
Huge Insider Buying in MGM and Salesforce
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
Crescent and Kelun-Biotech swap cancer asset rights in double deal
The partnership includes regional rights to Crescent’s bispecific antibody and Kelun’s ADC.
Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use
Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal.
Crescent Biopharma, Kelun-Biotech Biopharmaceutical Partner in Multimillion Dollar Deal to Develop Cancer Drugs
Crescent Biopharma (CBIO) and Japan's Sichuan Kelun-Biotech Biopharmaceutical said Thursday that the